Together, these observations suggest that increased expression of pro-inflammatory genes such as COX2, IL-8 and CCL2 may characterize the VDRff variant in breast cancer cells as a possible clinical marker for aggressive tumors. This evidence concerns the gene CCL2 and breast cancer.